132 related articles for article (PubMed ID: 35192890)
21. Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma.
Lu H; Zhang B; Xie Y; Zhao W; Han W; Zhou L; Wang Z
Invest New Drugs; 2023 Aug; 41(4):564-578. PubMed ID: 37322389
[TBL] [Abstract][Full Text] [Related]
22. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
23. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
24. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
25. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
26. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Stea B; Falsey R; Kislin K; Patel J; Glanzberg H; Carey S; Ambrad AA; Meuillet EJ; Martinez JD
Cancer Lett; 2003 Dec; 202(1):43-51. PubMed ID: 14643025
[TBL] [Abstract][Full Text] [Related]
27. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
28. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
29. Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination.
Tu Y; Chen Z; Zhao P; Sun G; Bao Z; Chao H; Fan L; Li C; You Y; Qu Y; Chen Y; Ji J
Clin Cancer Res; 2020 Apr; 26(7):1749-1762. PubMed ID: 31900278
[TBL] [Abstract][Full Text] [Related]
30. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
31. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
32. The antiproliferative and apoptotic effects of apigenin on glioblastoma cells.
Stump TA; Santee BN; Williams LP; Kunze RA; Heinze CE; Huseman ED; Gryka RJ; Simpson DS; Amos S
J Pharm Pharmacol; 2017 Jul; 69(7):907-916. PubMed ID: 28349530
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
34. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
[TBL] [Abstract][Full Text] [Related]
35. Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma.
Verreault M; Segoviano Vilchis I; Rosenberg S; Lemaire N; Schmitt C; Guehennec J; Royer-Perron L; Thomas JL; Lam TT; Dingli F; Loew D; Ducray F; Paris S; Carpentier C; Marie Y; Laigle-Donadey F; Rousseau A; Pigat N; Boutillon F; Bielle F; Mokhtari K; Frank SJ; de Reyniès A; Hoang-Xuan K; Sanson M; Goffin V; Idbaih A
Clin Transl Med; 2022 Jul; 12(7):e939. PubMed ID: 35808822
[TBL] [Abstract][Full Text] [Related]
36. Genistein inhibits radiation-induced invasion and migration of glioblastoma cells by blocking the DNA-PKcs/Akt2/Rac1 signaling pathway.
Liu X; Wang Q; Liu B; Zheng X; Li P; Zhao T; Jin X; Ye F; Zhang P; Chen W; Li Q
Radiother Oncol; 2021 Feb; 155():93-104. PubMed ID: 33129924
[TBL] [Abstract][Full Text] [Related]
37. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
[TBL] [Abstract][Full Text] [Related]
38. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
[TBL] [Abstract][Full Text] [Related]
39. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
Klingler-Hoffmann M; Fodero-Tavoletti MT; Mishima K; Narita Y; Cavenee WK; Furnari FB; Huang HJ; Tiganis T
J Biol Chem; 2001 Dec; 276(49):46313-8. PubMed ID: 11514572
[TBL] [Abstract][Full Text] [Related]
40. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]